

Clinical Trial Protocol

Iranian Registry of Clinical Trials

02 Jun 2026

Comparing the preventive effect of celecoxib on pain after ankle fracture surgery

Protocol summary

Study aim

Determining the effect of prophylactic administration of celecoxib on pain after ankle fracture surgery

Design

A clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3 on 55 patients. A table of random numbers will be used for randomization.

Settings and conduct

After obtaining informed consent, patients over 18 years of age who are candidates for ankle fracture orthopedic surgery will be studied in the operating room of Imam Hossein (AS) Hospital. People with uncontrolled underlying diseases, treated with drugs that affect pain, suffering from neuropathy, history of allergic reactions to NSAIDs, suffering from mental diseases, and any third use of drugs will be excluded from the study. Patients will be placed in one of the following groups by random block sampling method: 600 group, 400 group, and placebo group. Pain intensity was recorded using VAS (visual analog scale) and the incidence of nausea and vomiting during recovery and 6, 24, and 72 hours after surgery.

Participants/Inclusion and exclusion criteria

The conditions for entering the study include all patients over 18 years of age who are candidates for tibial bone fracture surgery. The conditions for not entering the study include people without significant underlying disease and neuropathy, and people who do not use pain-relieving drugs and do not abuse drugs.

Intervention groups

Patients in intervention groups receive different doses of celecoxib the night before surgery and one hour before surgery. The control group receives placebo capsules at the same time.

Main outcome variables

Postoperative pain

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20120910010800N11**

Registration date: **2023-05-06, 1402/02/16**

Registration timing: **prospective**

Last update: **2023-05-06, 1402/02/16**

Update count: **0**

Registration date

2023-05-06, 1402/02/16

Registrant information

Name

Dariush Abtahi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2263 2611

Email address

d.abtahi@sbmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-05-10, 1402/02/20

Expected recruitment end date

2023-06-10, 1402/03/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparing the preventive effect of celecoxib on pain after ankle fracture surgery

Public title

Effect of celecoxib on pain after orthopedic surgery

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Over than 18 years old Consent to the study

Exclusion criteria:

Substance abuse Uncontrolled underlying disease Underlying neuropathy

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **55**

Randomization (investigator's opinion)

Randomized

Randomization description

At the time of admission to the orthopedic department, the patients will be randomized using the permutation block method using random numbers obtained from the table of random numbers written on the card, which will be placed in sealed non-transparent envelopes, by an anesthesia technician who is in the stages. Next, there will be no interference plan, they will be placed equally in one of the following groups. Patients in the control group will receive two placebo capsules the night before surgery and one placebo capsule one hour before surgery. Group 400 patients will receive two celecoxib 200 mg capsules the night before surgery and one placebo capsule one hour before surgery. Group 600 patients will receive two 200 mg celecoxib capsules the night before the operation and another 200 mg celecoxib capsule one hour before the operation.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, 200 mg celecoxib capsules and placebo capsules will be used, in which the celecoxib content of the capsule is replaced with an approved artificial sweetener powder. These capsules will be placed inside the envelope during the preparation of the groups' envelopes and will be given to the patient by the ward nurse (the night before the operation) and the anesthesia technician (when entering the operating room), who will not be aware of the patient's next condition. The next follow-up of the patients and data recording will be done by the anesthesiologist who is not aware of the patient group.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Research Ethics Committees of Vice-Chancellor in Research Affairs - Shahid Beheshti University of Me

Street address

Next to Ayatollah Taleghani Hospital, Yemen Street, Shahid Arabi Street, Shahid Chamran Highway, Tehran

City

Tehran

Province

Tehran

Postal code

1985717443

Approval date

2023-04-30, 1402/02/10

Ethics committee reference number

IR.SBMU.RETECH.REC.1402.077

Health conditions studied**1****Description of health condition studied**

Bimalleolar fracture of lower leg

ICD-10 code

S82.84

ICD-10 code description

Bimalleolar fracture of lower leg

Primary outcomes**1****Description**

Postoperative pain

Timepoint

6, 24 and 72 hours after the operation

Method of measurement

Using Visual Analogue Scale

Secondary outcomes**1****Description**

Postoperative nausea and vomiting

Timepoint

6, 24, and 72 hours after surgery

Method of measurement

Patient's statement

Intervention groups

1

Description

Intervention group: Patients in the 400 group will receive two celecoxib 200 mg capsules the night before surgery and one placebo capsule one hour before surgery.

Category

Treatment - Drugs

2

Description

Intervention group: Group 600 patients will receive two 200 mg celecoxib capsules the night before the operation and another 200 mg celecoxib capsule one hour before the operation.

Category

Treatment - Drugs

3

Description

Control group: Patients in the placebo group will receive two placebo capsules the night before the operation and another placebo capsule one hour before the operation.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Hospital Emam Hossein

Full name of responsible person

Dariush Abtahi

Street address

Shahid Madani St

City

Tehran

Province

Tehran

Postal code

1617763141

Phone

+98 21 7756 7840

Email

drdariushabtahi@yahoo.com

Web page address

<https://www.ehmc.ir>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Afshhin Zarghi

Street address

Tehran Province, Tehran, Velenjak, 7th Floor, Bldg No.2, SBUMS, Arabi Ave

City

Tehran

Province

Tehran

Postal code

1983963113

Phone

+98 21 2243 9770

Email

Intl_office@sbmu.ac.ir

Web page address

<https://en.sbmu.ac.ir>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahid Beheshti University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Dariush Abtahi

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Emam Hossein Hospital, Shahid Madani St

City

Tehran

Province

Tehran

Postal code

1617763141

Phone

+98 21 2263 2611

Fax

Email

d.abtahi@sbmu.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Dariush Abtahi

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Emam Hossein Hospital, Shahid Madani St

City

Tehran

Province

Tehran

Postal code

1617763141

Phone

+98 21 2263 2611

Fax

Email

d.abtahi@sbmu.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Dariush Abtahi

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Emam Hossein Hospital, Shahid Madani St

City

Tehran

Province

Tehran

Postal code

1617763141

Phone

+98 21 2263 2611

Fax

Email

d.abtahi@sbmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

No - There is not a plan to make this available

Title and more details about the data/document

All data is potentially shareable after unidentified individuals.

When the data will become available and for how long

One year after the publication of the article.

To whom data/document is available

All jobs

Under which criteria data/document could be used

All non-personal patient information (anonymously) can be accessed by contacting the responsible author.

From where data/document is obtainable

Email to: drdariushabtahi@yahoo.com

What processes are involved for a request to access data/document

Sending email and review by the responsible author

Comments